Wils J, Utama I, Smeets J
Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
Oncology. 1988;45(6):413-6. doi: 10.1159/000226655.
Twenty-eight patients with stage III non-small cell lung cancer were treated with the sequential administration of combination chemotherapy consisting of epirubicin, cisplatin, and etoposide and of irradiation. The response rate was 57% including 15% complete responses. The median survival time was 11 months. Eighteen patients with stage IV disease received the same chemotherapy. The response rate was 55% including 11% complete responses, but the median survival time was only 5 months. It is concluded that this protocol is as active as the combination of doxorubicin, etoposide, and cisplatin, but probably less toxic.
28例Ⅲ期非小细胞肺癌患者接受了表柔比星、顺铂和依托泊苷联合化疗序贯放疗。缓解率为57%，其中完全缓解率为15%。中位生存时间为11个月。18例Ⅳ期患者接受了相同的化疗。缓解率为55%，其中完全缓解率为11%，但中位生存时间仅为5个月。结论是该方案与多柔比星、依托泊苷和顺铂联合方案疗效相当，但毒性可能较小。
